An international survey of classification and treatment choices for group D retinoblastoma
Year: 2017
Type: article
Study design: Observational Study
Abstract: AIM: To determine which IIRC scheme was used by retinoblastoma centers worldwide and the percentage of D eyes treated primarily with enucleation versus globe salvaging therapies as well as to correlate trends in treatment choice to IIRC version used and geographic region. METHODS: An anonymized electronic survey was offered to 115 physicians at 39 retinoblastoma centers worldwide asking about IIRC classification schemes and treatment patterns used between 2008 and 2012. Participants were asked to record which version of the IIRC was used for classification, how many group D eyes were diagnosed, and how many eyes were treated with enucleation versus globe salvaging therapies. Averages of eyes per treatment modality were calculated and stratified by both IIRC version and geographic region. Statistical significance was determined by Chi-square, ANOVA and Kruskal-Wallis tests using Prism. RESULTS: The survey was completed by 29% of physicians invited to participate. Totally 1807 D eyes were diagnosed. Regarding IIRC system, 27% of centers used the Children’s Hospital of Los Angeles (CHLA) version, 33% used the Children’s Oncology Group (COG) version, 23% used the Philadelphia version, and 17% were unsure. The rate for primary enucleation varied between 0 and 100% and the mean was 29%. By IIRC version, primary enucleation rates were: Philadelphia, 8%; COG, 34%; and CHLA, 37%. By geographic region, primary enucleation rates were: Latin America, 57%; Asia, 40%; Europe, 36%; Africa, 10%, US, 8%; and Middle East, 8%. However, systemic chemoreduction was used more often than enucleation in all regions except Latin America with a mean of 57% per center (P<0.0001). CONCLUSION: Worldwide there is no consensus on which IIRC version is used, systemic chemoreduction was the most frequently used initial treatment during the study period followed by enucleation and primary treatment modality, especially enucleation, varied greatly with regards to IIRC version used and geographic region.
Authors: Christina Scelfo, Jasmine H Francis, Vikas Khetan, Thomas Jenkins, Brian Marr, David H Abramson, Carol L Shields, Jacob Pe’er, Francis Munier, Jesse Berry, J. William Harbour, Andrey Yarovoy, Evandro Lucena, Timothy G Murray, Pooja Bhagia, Evelyn Paysse, Samuray Tuncer, Guillermo L Chantada, Annette C Moll, Tatiana Ushakova, David A Plager, Islamov Ziyovuddin, Carlos A Leal, Miguel A Materin, Xun-Da Ji, Jose W Cursino, Rodrigo Polania, Hayyam Kiratli, Charlotta All-Ericsson, Rejin Kebudi, Santosh G Honavar, Vicktoria Vishnevskia-Dai, Sidnel Epelman, Anthony B Daniels, Jeanie D Ling, Fousseyni Traore, Marco A Ramirez-Ortiz
Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, Sankara Nethralaya, Thomas Jefferson University, Wills Eye Hospital, Hebrew University of Jerusalem, Hadassah Medical Center, Hôpital Ophtalmique Jules-Gonin, University of Southern California, Children's Hospital Los Angeles, University of Miami, University of Miami Health System, Intersectoral Research and Technology Complex Eye Microsurgery, Instituto Nacional de Câncer - INCA, Miami Children's Hospital, St. Joseph’s Children’s Hospital, Baylor College of Medicine, Istanbul University, Garrahan Hospital, Amsterdam UMC Location Vrije Universiteit Amsterdam, Russian Cancer Research Center NN Blokhin, Riley Hospital for Children, Instituto Nacional de Pediatria, Yale University, Smilow Cancer Hospital, Shanghai Jiao Tong University, XinHua Hospital, Irmandade da Santa Casa de Misericórdia de São Paulo, Fundación Valle del Lili, Hacettepe University, S:t Eriks Ögonsjukhus, Istanbul University-Cerrahpaşa, Sheba Medical Center, Hospital Santa Marcelina, Vanderbilt University, Vanderbilt University Medical Center, Hospital Infantil de México Federico Gómez
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,800
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W2734845189